DaVita Inc. (DVA) Earnings Call Transcript & Summary
July 30, 2020
Earnings Call Speaker Segments
Jim Gustafson
executiveThanks for joining us for the second-quarter earnings call, and welcome. We're grateful that you continue to follow what's happening at our company. Speaking is Jim Gustafson, and I serve as Vice President of Investor Relations. With me today, participating remotely, are our CEO Javier Rodriguez, our CFO Joel Ackerman, and Group Vice President LeAnne Zumwalt. Be aware that we might present forward-looking statements on this call as defined under the federal securities laws. Known and unknown risks and uncertainties apply to all such statements, and those factors might lead actual results to differ materially from what the forward-looking statements describe. To learn more about these risks and uncertainties, please see our Q2 earnings press release as well as our SEC filings, which include our latest annual report on Form 10-K and later quarterly reports on Form 10-Q. The forward-looking statements we make rest on information available to us at present, and we neither intend nor assume any obligation to revise them. GAAP financial measures. You can find a reconciliation linking these non-GAAP measures to the closest comparable GAAP financial measures in our earnings press release, which has been filed with the SEC and is posted on our website. At this point I'll hand the call over to Javier Rodriguez.
Javier Rodriguez
executiveThanks, Jim. Hello, everyone, and good afternoon. We appreciate you being with us for the Q2 earnings discussion. To begin, I'd like to do what I did three months ago: recognize and express gratitude to each of our teammates, particularly the many thousands of clinicians delivering life-sustaining treatment to our patients day in and day out. These last several months rank among the best and most remarkable periods in the story of our company, and they showcase the caring and commitment of the people who work here. The solid results we posted this quarter show what our comprehensive, patient-focused kidney care platform can do, from CKD through ESRD and transplant. Because we provide uninterrupted care, we can serve patients wherever they happen to be, offering modality choices in the hospital, at home, or at the dialysis center. We are approaching the six-month mark of this pandemic. Step inside any of our centers, and you would still find a great deal of energy and intensity among our teammates as they look after our patients' health and safety. We took the infection control measures that were already working well and added COVID testing for patients and teammates, using both our in-house lab and special partnerships with outside labs; these efforts, guided by physicians and clinicians, let us care for as many patients as possible outside the hospital, which helps patients and takes strain off hospitals. Nobody can say for sure what lies ahead, but I can tell you we feel prepared to continue doing what's necessary to safeguard our patients and teammates. Our Q2 financial results came in strong. On that basis, we're raising our full-year adjusted earnings per share guidance by $0.50, which brings it to $6.25-$6.75. We delivered that strong operational performance despite the spending and expenses we absorbed responding to COVID — partially balanced out by pandemic-driven reductions in travel and health benefit costs, plus additional items Joel will cover in more detail. There are four further subjects I'd like to cover today. To start, I'll speak to treatment volumes and commercial mix, the pair of largest uncertainties connected to the pandemic that we flagged a quarter ago. Our patient census has taken a hit mainly from COVID-related deaths and from patients starting dialysis later than usual, and we anticipate treatment volumes for the rest of the year will come in under the bottom of the 1.5%-2.5% range we gave in September. The patients who sadly died from COVID were largely in our older population, so they tended to have government insurance more often. Consequently, we have so far not experienced a significant adverse effect on our commercial mix. That said, with just three months of real data regarding job losses, any conclusions about our commercial patient population and whether they can obtain private rather than government health insurance remain tentative. Here's what we can say for certain: during the quarter, our census of private patients held up more strongly than we had anticipated, since the people we serve are working diligently to keep both their jobs and their insurance. Although how COVID will affect things over the long haul is still not clear, certain natural offsets are present, and our confidence in the durability of our business model remains firm. Turning to the second subject, I want to walk you through some encouraging news regarding our home business. As everyone is aware, we begin from a leading spot in home, with roughly 14% of our patient population on a home modality and over 25% using a home modality at some point along their care journey. Growth in our home business keeps exceeding growth in our in-center dialysis business by a factor of more than five, and throughout the pandemic, we've noticed a modest rise in interest among patients who want to dialyze at home. At present, we have more than 28,000 home patients receiving training, education, lab draws, and medication at over 1,750 programs throughout the U.S. In fact, 95% of dialysis patients reside within 30 miles of a DaVita home program. Our home business has reached this size because we've put years of work into building up our capabilities, training, and technology, all so that patients and doctors can choose home dialysis whenever it works for them. Here are two illustrations. To start, a number of years back, we introduced a platform for remote monitoring at home, and it lets us check the vital signs each day for roughly 5,000 patients who are at high risk. Then, at the beginning of last year, we brought out a strong telehealth platform designed for home use, and it currently serves more than 19,000 patients. Lately, we've kept expanding those platforms so they can deliver things like remote programs for managing a disease, online groups where patients support one another, and tools that help keep care consistent and assist patients who leave the hospital in continuing treatment at home. Our view is that with these features, we've been able to reach home patients far more often, which helps us keep raising the standard of care and helps lengthen how long those patients stay on the therapy. Having telehealth up and running already also gave us a big edge in our capacity to keep patients and the people caring for them in touch throughout the pandemic. Another development we're eager to share involves rolling out our AI-driven tool designed to flag PD patients who could face elevated chances of being hospitalized — a major factor behind home patients moving to in-center dialysis. Expanding home treatment and pushing innovation remain high on my list of priorities, and we keep testing numerous fresh initiatives and concepts across various regions to assist patients for whom home dialysis works best. On top of that, we think having every modality available lets us guide patients smoothly toward the appropriate option at the proper moment along their dialysis path. Thanks to our nationwide reach, the partnerships we have with physicians, and what we alone can do, patients keep getting better outcomes as we aim to set the pace in expanding care at home. Calcimimetics is the third subject I want to cover. You're probably aware that reimbursement for calcimimetics is entering its subsequent stage, since CMS, in the proposed payment rule for 2021 it released not long ago, suggested placing calcimimetics inside the Medicare Bundle Payment; our view is that the TDAPA window allowed CMS adequate opportunity to look at how the drug was being used and what it cost, particularly given how IV therapy and oral therapy are mixed. Across the past 2 years, the doctors and clinical staff working with us created protocols centered on patients that let us hit the demanding quality benchmarks we set for care, and here that also brought down what health systems had to pay, since following the protocol meant more use of inexpensive generics and less use of pricier IV options. Under the new rule, we expect calcimimetics to produce economics in 2021 comparable to what we projected for 2020, and that should help counterbalance the shortfall in funding for the rest of the Medicare bundle. Medicare Advantage is the final subject I'll raise. Many of you know that back in 2016, the 21st Century Cures Act was passed by Congress so that every patient eligible for Medicare, ESRD patients included, could choose to sign up for Medicare Advantage plans. In our view, removing the obstacles that kept patients on active dialysis from joining Medicare Advantage will prove beneficial for a great many patients, providers, and managed care organizations, because this new rule widens the chance to deliver coordinated care to patients dealing with several chronic conditions at once. Sadly, by loosening MA network adequacy requirements for dialysis services alone in its recent ruling, CMS raises doubts about how broad the options truly are for dialysis patients. We lack clear visibility, yet we still hold the belief that ESRD patient sign-ups for Medicare Advantage plans will happen little by little across the next year. Now I'll hand things to Joe, who will update you on our Q2 results and walk through our financial outlook.
Joel Ackerman
executiveThank you, Javier. Despite the net headwind created by how we responded to COVID, we delivered a solid quarter, driven mainly by better adjusted margins in our core kidney care operation. Let me walk through some details. Growth in non-acquired treatments decelerated from 2.3% during Q1 to 1.6% during Q2; in our view, this decline came mostly from COVID-related causes, since higher mortality and fewer new patients starting treatment were partly counterbalanced by a nationwide drop in kidney transplants and fewer missed treatments; we anticipate this net COVID NAG headwind will stick around at least through this same point next year. Total revenue matched what we had expected, since lower volumes were offset by higher revenue per treatment. RPT rose because of typical seasonality in co-insurance and deductibles plus the temporary Medicare sequestration release, partly offset by reduced calcimimetics revenue. As Javier mentioned, although COVID's long-term effects are still uncertain, we observed no net change to our commercial mix from one quarter to the next. Several factors, we think, explain this pattern, including, among other things, that the rate of job loss among our commercial patient population came in below the national unemployment rate. A large share of our commercial patients who were furloughed at first have by now gone back to work or anticipate doing so. Lastly, we believe our patients who lost their jobs have been signing up for other commercial insurance, including COBRA and Exchange plans, more often than we have observed previously. Adjusted operating income margin came in strong at 16% for the quarter. Compared with a year earlier, our margin grew thanks to robust cost management throughout the P&L and an improvement in RPT. Calcimimetics added roughly $19 million to our operating income during Q2. Let me share some specifics regarding how COVID affected our financial results. For Q2, we estimate we took on expenses and other negative effects on our operating income of roughly $85 million. Additional compensation and benefits for our teammates represented the biggest piece of these costs. Offsets during the quarter against that $85 million include, among other things, less travel, reduced health benefits expenses, and lower facility and training costs. We also benefited from the temporary halt on Medicare sequestration that began in May. Thanks to these offsets, we estimate the net impact of COVID on our operating income for the quarter landed between $20 million-$30 million. Turning to the H2 of 2020, COVID's impact is difficult to predict given how uncertain the virus's trajectory and the economic consequences are. Although extreme situations beyond our range could arise, we have built a broad set of scenarios into our updated guidance, including scenarios where the net financial impact of COVID-19 in each of Q3 and Q4 might resemble what we saw in Q2. Let me now move to our 2020 guidance. Because of how strong our H1 performance was, we are updating our guidance ranges. Our adjusted diluted EPS outlook is moving up by $0.50, bringing the range to $6.25-$6.75. For adjusted operating income margin, we're lifting the guidance range to 14%-14.75%. Cash flow guidance is being raised to $800 million-$1 billion — that's $200 million more than the range we gave previously. Revenue guidance stays at $11.5 billion-$11.7 billion, though we now anticipate landing under the midpoint because volume growth is expected to slow. Turning to capital expenditures, we had offered an estimated range of $700 million-$750 million. We now anticipate finishing at the lower end of that range, since the pandemic pushed back some project spending. Although we aren't giving specific 2021 guidance today, I'd like to call out several of the bigger expected headwinds and tailwinds relative to our 2020 non-GAAP adjusted operating income. The main headwinds we expect are the volume and mix effects of COVID. Among the main tailwinds we expect are the assumed absence of ballot initiative defense costs and, hopefully, a decrease in net COVID-related direct impact. Regarding calcimimetics, we still must await CMS's final rule later this fall, but we don't anticipate calcimimetics becoming a significant headwind or tailwind to adjusted OI. Last, on share repurchases: back in March we said we were temporarily pausing buybacks; no shares were repurchased by us in Q2 or in July. We're giving careful thought to when buyback activity should resume, and it will happen at management's discretion and within the authorization our board of directors has provided. With that, operator, please open the line for Q&A.
Pito Chickering
analystMorning, everyone. I appreciate you fielding my questions. Could you expand a bit on the operating income outlook? When we look at the first half, at 16.2%, even with all those COVID expenses, the margin implied for the second half seems to land somewhere around 12% to roughly 13.4%. That's quite a significant drop. Can you take us through how we arrive at that figure? Does it come from treatment growth flowing through? Please walk us through the specifics of how we end up with such a sizable margin compression in the latter half of the year.
Joel Ackerman
executiveAbsolutely. Hi, Pito. I'll handle this one. If you take the midpoint of our range — though to be clear, we aren't providing guidance on OI — using the middle of our guidance, I believe you'd arrive at an OI decrease of approximately $175 million when comparing the first half to the second half. The three largest pieces of that are: first, lower calcimimetics profits, which, as we've mentioned previously, make up most of our figure — our $40 million to $70 million — and incidentally, we anticipate that figure landing in the upper half of that range. The bulk of that lands in the first half. Second, the California ballot initiative. We've described that as costing $0.50 a share, and it falls mainly in the second half. Third, I'd highlight COVID. While the expenses tied to COVID might decrease as the year progresses, the offsets might decrease as well, and we're applying a fairly broad range of assumptions regarding what might unfold in the second half with COVID. But the second half will contain two quarters' worth of COVID, whereas the first half really only had one quarter's worth. Combine those three factors, and you'll account for the vast majority of that $175 million decrease. A few other items I'd mention. First, there were some fairly minor one-time items in the first half that boosted OI, and there may be some unfavorable one-time items in the second half. Lastly, due to COVID and possibly other factors, there are certain costs we didn't incur during the first half, and we believe those might appear in the second half — anything from G&A projects to facility maintenance — and those would be the remaining two pieces that bring you to that $175 million adjusted OI decline at the center of the guidance range.
Pito Chickering
analystOkay, and as a second question, can you give us more detail about the final Medicare Advantage regulation? Please explain how it affects your negotiations with MA plans. For the 2021 event, when do you anticipate starting to see impacts from the updated rule, or is it more gradual because multi-year contracts are spread out? During your discussions with MA plans, has there been any talk of bonus payments for improved patient management, or is that too early? Finally, if MA plans do not certify a network that is overly narrow, what checks and balances are in place?
Javier Rodriguez
executivePito, I'll handle that, and Joel, if you want to chime in — you brought up a number of points. Should I miss any point, feel free to press me on it once more. The brief response is that the consequences remain unclear to us. What we can say for certain is that regarding network adequacy, an objective benchmark based on time and distance existed previously, whereas today the measure is subjective. That could amount to nothing at all. It could also mean plans simply attest now and things continue just as they always have. Alternatively, certain plans might take an aggressive approach and operate without sufficient network standards; it's premature to say, though in our view, this amounts to pulling out and discriminating against ESRD patients. Without proper network adequacy, you are essentially deterring enrollment. To us, this is simply something out of the ordinary, and it violates what patients are entitled to. The ESRD population waited an extremely long time to be treated the same as everybody else, and they ought to have the ability to choose MA the same way other people do. That piece was disheartening. When it comes to bargaining, like you mentioned, the majority of our MA plans are under agreements spanning multiple years. We're engaging with them. Our belief is that together we can collaborate effectively, can address MLR, and can accomplish genuinely positive outcomes for patients when it comes to coordinating their care. It's premature to say, since only a small number of contracts have taken place.
Pito Chickering
analystRight.
Javier Rodriguez
executiveDid I miss any of your question?
Pito Chickering
analystNo. I suppose the final item would be this: what are the checks and balances? Should the MA plan be required to self-certify, what mechanism exists to guarantee they won't self-certify a network that's overly narrow?
Javier Rodriguez
executiveYeah. That's a piece of the issue. At present, it enters some sort of subjective attestation that their network is proper. From where we sit, naturally, what we're doing is keeping our radar up to ensure the spirit of the law is followed, but how it'll be enforced is unknown to us.
Pito Chickering
analystGreat. Thanks so much.
Javier Rodriguez
executiveThank you.
Kevin Fischbeck
analystGreat, thank you. I wanted to perhaps build on that point, if I may. You said the majority of your agreements span multiple years. So does that imply you're heading into 2021 with economics in your MA plans that are fairly close to what you have now in 2020?
Javier Rodriguez
executiveYes, I'd say that's a reasonable way to put it. In any particular year, renegotiations happen, yet that's true annually. Occasionally they coincide, but at this point that assumption seems fair. Naturally, we still have the latter part of the year remaining for negotiations. Both we and the plans feel a strong desire to pursue something beneficial and inventive for the system, allowing us to assume greater risk and deliver more advanced services to patients. The discussions are ongoing. We'll find out how it turns out.
Kevin Fischbeck
analystRight, my guess is that this only took place a couple of months back, so perhaps not a lot of contracts have actually been put in place yet. My assumption is that you're always talking with health plans — does it seem like they're getting ready for aggressive changes right now, or do you have any read on that?
Javier Rodriguez
executiveYeah, Kevin, I think the truth is that everyone is attempting to do something constructive when it comes to giving patients this chance at coordinated care. The plans and we are both trying to figure out their appetite for risk, what our system is capable of, what their system is capable of. There's a strong desire on both sides to do something that benefits this patient population. We'll find out how that plays out over time.
Kevin Fischbeck
analystAt some stage during this year, do you figure you'd have a clearer read on things by the time the Q3 call happens? Will your visibility basically be solid enough for at least 2021, or must we hold off until the Q4 results come in?
Javier Rodriguez
executiveMy sense is that it will need a bit more time to unfold, given how expirations and the timing of contracts coming up interact, plus the fact that I can't predict what effect COVID will have on negotiations. If you made me guess, I'd say it takes somewhat longer than that.
Kevin Fischbeck
analystJoel, on the calcimimetics side, my read is you expect it to be earnings-neutral in the coming year. If you're generating roughly $70 million in the current year, the assumption is that next year lands at a comparable figure. Is that the correct framing?
Joel Ackerman
executiveYes. There's still some uncertainty around next year, though one possible outcome was that OI dropped to zero. Against that backdrop, we believe we're positioned far more favorably, and 70-ish strikes me as a sensible midpoint for the range. That said, I want to flag one item that matters for how we view OI going forward: we've identified calcimimetics as what I'd term non-recurring, given the TDAPA period and how TDAPA reimbursement works. It isn't permanent. Once this moves into the bundle next year, I'd treat the OI we're producing from calcimimetics as belonging to our core OI, since the funding is permanent and it's a permanent piece of the bundle. We'll cease calling it out, and to my mind it becomes part of the business's core earning power.
Javier Rodriguez
executiveKevin, let me just mention one more thing in case a few people find it unclear. The reason there isn't an exact figure from us — and Joel provided something of a range — comes down to CMS adjusting that amount using Q4 ASP, and rather than a precise figure, what we have is an estimate.
Kevin Fischbeck
analystAlright, that's all clear. My take is that during the first half of next year it works against us, yet once we get into the back half, compared with the same period a year earlier, it becomes a positive, since the effect will be evenly distributed across the twelve months rather than concentrated at the start like it is this year.
Joel Ackerman
executiveThat strikes me as a sound way to look at it.
Kevin Fischbeck
analystOkay, so perhaps one final question—it wasn't fully clear to me. You talked about the reason the commercial mix came in strong. I believe you said some things regarding your patients enrolling in COBRA and purchasing other coverage. That part makes sense to me, but regarding those remarks about reduced job loss and similar points, could you walk back through what you meant there and why it might be that, up to now at least, job loss has had a smaller effect on your patients than one would anticipate?
Joel Ackerman
executiveCertainly. Three forces are shaping mix. The unemployment issue is among them, so I'll address it. We pointed to three items. First, job loss within our population is below the national averages we observe; our thinking is that this stems from the employment composition—I'm not sure what label to give it—of our commercial population tilting more toward fields such as government and education and tilting away from fields such as hospitality and travel. The industries where our patients are employed have felt a smaller hit from COVID's economic consequences. That's the first. Second, much of the unemployment we observed among our population came from furloughs instead of job losses, and many of those have been undone. Those patients never had their coverage interrupted, and they are now back on the job, or they anticipate returning to work. Third, when our patients have seen their employer-based commercial coverage disappear, they have made considerable effort to secure alternative commercial coverage, whether via COBRA or the exchanges. We are observing that occur at a greater rate than we have historically witnessed. Even so, we lack substantial historical experience with exchanges, since exchanges did not exist at the time of the Great Recession in 2008 and 2009. That's the reason we believe we are seeing a smaller mix decline on commercial tied to unemployment. I would add as well that mortality actually helps commercial mix over the short term, since older patients are dying at a greater rate than younger ones, and government patients skew older while commercial patients skew younger; that is providing a boost. And the drop in transplants is providing a boost too. Commercial patients receive transplants at a far greater rate than government patients.
Javier Rodriguez
executiveKevin, there's one point I want to make — a big-picture lesson that's come out of all this. What we've heard while speaking with our commercial patient has genuinely driven home just how much effort our patients put in to hold onto their commercial insurance, and how highly they regard it. That's been an unmistakably clear takeaway from this stretch.
Kevin Fischbeck
analystAll right, great. Thanks.
Javier Rodriguez
executiveThank you.
Andrew Mok
analystHello, and good afternoon. I appreciate you taking the question. I just wanted to ask a bit more about Medicare Advantage. With the fall open enrollment period coming up, how aware are your traditional Medicare patients that they will be able to sign up for a private Medicare plan during this fall? And on a related note, what kinds of patient education initiatives are you undertaking regarding this subject? Thank you.
Javier Rodriguez
executiveYes, I'll take that one. As one might anticipate with any group facing something new, the level of information varies widely, ranging from those who are well informed to those who know nothing at all about it. We are putting a lot of effort into providing completely impartial and factual instruction that is tailored to each individual, so it can be viewed through your own personal lens, since what makes a good insurance choice for one individual may not be a good insurance choice for another, depending on your secondary coverage, your family's requirements, or your stage in life. Our primary goal is for individuals to have a well-rounded view, to know what options they have, and to actually select what suits them best. The level of understanding is quite scattered.
Andrew Mok
analystUnderstood. All right, I was hoping to dig a bit deeper into how well costs were controlled during the quarter. Could you share a few figures regarding the productivity improvements and G&A savings that showed up in Q2, and what portion of those you believe can carry forward as we move into 2021? Thanks.
Joel Ackerman
executiveYes. On both of those items, there isn't anything specific I would highlight. Regarding G&A, there may be somewhat of a concern about whether some of that will be returned in the back half of the year, and that ties into part of the half one over half two bridge I mentioned earlier in the call. Beyond that, I wouldn't point to anything out of the ordinary.
Andrew Mok
analystAll right, thank you.
Justin Lake
analystThank you. Good afternoon. I appreciate that. Just one additional item regarding Medicare Advantage networks. Javier, it caught me off guard a bit when you replied to an earlier question by saying you might not be aware of how the networks appear by your next fall. From what I understand about MA, the plans need to release their products by, I believe, mid-October. At that moment, aren't they required to make their networks public? Wouldn't you be aware of whether you're inside or outside a network at that moment, for 2021 at the very least?
Javier Rodriguez
executiveYes, that's completely right, Justin. Perhaps I was responding to a separate question, which is, I believe what I was addressing is, will you grasp the sustainability or whether there will be macro shifts; regarding short-term networks, I don't expect anything significant to shift. I might be caught off guard, but that's not what I expect. What I was addressing is how will it shift as time goes on? I figured that by that point we would not observe how it'll perform across a prolonged stretch of time.
Justin Lake
analystUnderstood. What I'm hearing is that based on what you've told us, and considering how far into the year we already are, it seems unlikely that DaVita would be dropped from a Medicare Advantage network for 2021, though there might be some reassessment down the road in 2022 and 2023 regarding pricing and how networks are structured.
Javier Rodriguez
executiveRight. To put it another way, you get a few at-bats, but you won't hold a major piece of a portfolio or anything like that — that plays out gradually. Your assumptions are on target that come fall, we'll have clarity, but as you're aware, you could be in-network in the fall, and then a month or two afterward, you could find yourself out of network. I'm not sure how much you can rely on that fall in-network statement continuing to hold going forward.
Justin Lake
analystUnderstood, thank you. So I'd like to follow up regarding — and Joel, apologies if this was already covered — but revenue per treatment rose quite a bit on a quarter-over-quarter basis. Could you walk us through as much as you can, especially since calcimimetics appears to be coming down? When you strip out calcimimetics, what does that figure look like, along with the quarter-over-quarter gain, and which main factors should we be paying attention to?
Joel Ackerman
executiveAbsolutely. Removing calcimimetics, the range is $5 to $6. We're discussing the change in RPT from one quarter to the next. A significant portion of that comes from seasonality — think co-insurance and deductibles, plus somewhat reduced bad debt tied to patients moving through those. That's easily the largest driver. Everything else is simply, I'd call it, normal fluctuation in MA mix and commercial mix, along with a slight pricing element. The bulk of it reflects seasonal effects.
Javier Rodriguez
executiveRight, Joe — the one additional point I'd make on top of what you said is that some sequestration is included in that as well.
Joel Ackerman
executiveRight. Oh, absolutely — that is—
Justin Lake
analystThat's great.
Joel Ackerman
executiveI'd lost track of that one. Thanks, Javier.
Justin Lake
analystYeah, same here. That makes sense.
Joel Ackerman
executiveApologies, Justin — I want to make sure it's clear that sequestration was excluded from the figure I provided. That 5 to 6 did not include sequestration.
Justin Lake
analystWithout sequestration.
Joel Ackerman
executiveSequestration is worth about $1.50.
Justin Lake
analystAlright, since we're discussing this, how much did calcimimetics contribute?
Joel Ackerman
executiveI figured somebody would bring that up. My recollection is $0.50, but I'll follow up with the precise figure.
Justin Lake
analystAre we talking about profit here, or revenue?
Joel Ackerman
executiveOh no, my mistake. Please disregard that $0.50 figure. For calcimimetics, RPT dropped from $9.55 to $7 — a decline of roughly $2.50 driven by calcimimetics RPT. Now for OI: the dollar figure moved from $35 million in Q1 down to $19 million in Q2.
Justin Lake
analystAll right, on the commercial mix and commercial treatment growth side, your point is that mix stayed flat, so growth in commercial patients was roughly in line with total patient growth? Mix wasn't really a factor when it comes to that $5 to $6.
Joel Ackerman
executiveCorrect.
Justin Lake
analystWould you say this is a sensible figure from which to build once we exclude the calcimimetics? Should we treat that as a solid number for the third and fourth quarters?
Joel Ackerman
executiveThat strikes me as a fair place to begin, though I believe you'll notice unfavorable seasonality during Q1. That pattern should show up in the coming year. Please don't treat it as a yearly run rate; instead, treat it as the figure to apply across the upcoming two quarters.
Justin Lake
analystAlright, excellent. I'll rejoin the line later. Appreciate it.
Whit Mayo
analystThank you. I'm still attempting to grasp the core growth that was implied this quarter. Normally, you folks possess extraordinary insight regarding numerous expenses when you establish your initial plan, and currently we're seeing a figure that's significantly larger. It definitely appears to suggest that something improved considerably. I'm quite interested in what that might be, since when we exclude the COVID cost and calcimimetics, the sequester, all the items you've described, well, according to my calculations, it suggests core OI rose 8% compared to the prior year. I'm merely attempting to approach this from the perspective of the cost structure. Once more, is there anything additional you could identify that arrived substantially beneath what your initial forecasts were at the start of the year?
Joel Ackerman
executiveWhit, if I were going to attempt to clarify why the figures exceed our projections, initially, everything is core margin. Nothing out of the ordinary exists here. The core business is doing well. I would highlight productivity coming in somewhat superior to what we anticipated. Facility costs are somewhat superior to what we anticipated. RPT is slightly superior, though that gets offset considerably by volume coming in light. Consider core margin mostly propelled by solid cost management.
Whit Mayo
analystAll right. Could we quantify anything related to either COBRA or the exchange uptake? What I mean is, I assume you hold quite a bit of internal information on your patients and the coverage they have, and I'm simply attempting to understand the conversion rate into COBRA, since my assumption is that it's pretty high. I figured I would just try asking the question in a slightly more direct manner.
Javier Rodriguez
executiveI've considered what you're asking. That detail isn't something we make public, but my sense is that what you're after, in a directional way, is whether we have a significant COBRA spike that 18 months from now, or at some future date, will come home to roost. Is that a fair description of where you're headed?
Whit Mayo
analystNo, that's not what I was getting at at all. Honestly, the way this is being discussed out there is that your commercial mix matters enormously to you, so there's been worry about that, and my argument is that many of these patients discover other choices available to them, and a sizable share, a large percentage, get coverage via COBRA. Actually, it was the complete reverse of that premise.
Javier Rodriguez
executiveNo, what I'd say is basically what we mentioned before, and I believe that lines up with your point. Sure, that patient population is something our business depends on tremendously. We've been really struck by how eager our patients are to hold onto their commercial coverage by whatever means. Like Joel mentioned, being furloughed is quite different from losing a job permanently. We've observed that a substantial portion of our patients who work and had been furloughed have returned to their jobs. Among those whose job loss was permanent, and again that figure came in below what we expected, a lot have obtained other coverage. I believe that addresses every part of it.
Whit Mayo
analystNo, that's useful. Perhaps one final item — this might be an unanswerable question, but I figured I would pose it anyway. Javier, if there were a Biden administration, what would that signify for DaVita and for the sector? The charitable premium rule has been parked at the OMB for an eternity. Clearly, it existed during the previous administration. Nobody can say whether it comes back to life. I have zero clue where things stand with it. Public option Medicare expansion almost never came up during these calls. Perhaps all of us are simply savvy enough to hold more doubt about policy matters like this. I would simply be interested in your broad perspective on what a Biden presidency would entail.
Javier Rodriguez
executiveYeah, that is an excellent question, and it's something we have discussed; broadly speaking, our aim — and we've managed this reasonably well — is ensuring we engage with Republicans as well as Democrats, since the matter we deal with spans both camps. The most significant shift we could imagine regarding policy is likely on the tax front, and whether they can — should a Biden Administration exist, and whether you additionally control the Senate or not, that will clearly serve as a major force shaping tax policy. When it comes to healthcare policy, as you're aware, it is, as you noted, a far heavier undertaking to alter, and we will naturally play a role in that. Our goal is to keep pressing and advocating on behalf of our patients and for integrated care, no matter who occupies the White House.
Whit Mayo
analystOkay. Thanks a lot.
Javier Rodriguez
executiveThank you.
Javier Rodriguez
executiveHi, Gary.
Gary Taylor
analystHello there, good afternoon. I'd like to revisit a subject that's come up in a few variations, and I'll pose it somewhat differently, to see whether I can obtain a bit more assistance. Clearly, tremendous work when it comes to managing expenses. Perhaps Q2 is proving to be the standout quarter for cost control. Previously you'd outlined up to an additional $100 million in COVID expenses, roughly $13 per treatment, and I definitely didn't expect patient care costs to rise by $0.62 from one quarter to the next. I've caught the remarks regarding productivity, facility costs, health benefits. So, could we perhaps dig a bit deeper into where the productivity is coming from? I recall that for a stretch, I believe an extra $100 each month was being paid to a substantial portion of your teammates, which is somewhat the reverse of productivity. You'd arranged certain split shifts in order to separate patients who were COVID positive or suspected. The overall expectation, I suppose, was that this would be the reverse of a very robust productivity quarter, and yet your performance has been truly excellent. Perhaps just a few illustrations of how you're achieving this productivity, and what about facility costs, and was the health benefits component simply your own staff using less healthcare, and was that fairly significant? I know you've fielded this question multiple times, so any additional detail would simply assist us in trying to think through modeling ahead.
Javier Rodriguez
executiveQuite a bit is happening, and Gary, we take great pride in the cost management situation. Let me attempt to be as useful as I can, since there are multiple factors. To begin, one point of clarification. Indeed, regarding our healthcare spending, our teammates, just like everyone else, made less use of benefits for non-essential care. That's the first one. Second, our caregivers' sense of purpose was truly fervent, and as a result, we experienced reduced turnover since people felt that calling to look after our patients. The mix of financial necessity plus valuing having a job while so many others were furloughed or laid off, along with the dedication to our patients, meant lower training costs. The final point I'd mention is that a number of our teammates were also COVID positive. What we wound up doing was, in certain locations such as New York and elsewhere, where staffing was truly scarce, we essentially had to proceed. When you cohort centers and so forth, which is what you referenced before, at times those shifts weren't as inefficient as we'd expected, because those shifts had a tendency to be fuller than originally anticipated. If your COVID positive shift is full, even in a cohort arrangement, it isn't inefficient. The genuinely inefficient scenario is when you've got one or two patients in it. The accumulated math built up across the quarter, and we were extremely diligent in attempting to manage all of it.
Gary Taylor
analystThat's useful. Just a couple more fast questions; regarding that $35 million legal charge, did it tie back to some legal matter previously revealed in your filings, or was it a professional liability matter, or anything else you can share?
Joel Ackerman
executiveYeah, Gary, I'll handle that one. It concerned shareholder litigation that has been sitting around for several years, tied to CPA. Our position is that our actions were suitable, but simply to put this behind us and proceed, we judged it worthwhile to resolve it; it connects to that matter.
Gary Taylor
analystThanks. And then one final item, which I'd lost track of. What explains the gap between the 0.7% gain in treatments per day and the 1.6% normalized figure, given that treatment days are identical at 78.0/78.0? The calendar can't be responsible, and as far as I recall there were no divestitures. I'm simply attempting to remember how that gap gets reconciled.
Joel Ackerman
executiveRight. Divestitures and a few other items create plenty of noise, yet one significant item stands out that I'd point to: as of the first of the year, a group of clinics got deconsolidated, and those treatments would be removed from NAG, yet the treatment count keeps them in. In my view, that accounts for roughly 50 basis points of the gap.
Gary Taylor
analystAll right. Thanks very much.
Matt Larew
analystHello, and good afternoon. I'd like to inquire a bit regarding the footprint. I believe during Q1 we heard, when it comes to the footprint build, that you possibly mentioned a wait-and-see approach regarding what occurs with industry volumes and what occurs on the home side, and clearly, 28 new centers, and then possibly added to that following a couple of years of a somewhat stagnant OUS number. I'm aware there was considerable rationalization taking place. Over the last four quarters, you've now added roughly 40 new centers OUS. Perhaps just an update regarding development, on both the U.S. and OUS side.
Joel Ackerman
executiveYes, I'll handle that one, Javier. As you'd anticipate, most of the activity is on the U.S. side. The figure there is somewhat of a lagging indicator since it hinges on when CMS certifies us. If you desired to consider a figure that aligned more closely with the decision-making and the CapEx figure, it would rest on when the clinics are finished, which we refer to as a certificate of occupancy, and you'd observe that figure considerably lower. Regarding next year, I don't wish to provide a range at this point, but you'll observe that figure drop significantly once more. I believe moving forward, people wish to grasp how we're performing when it comes to building capacity and being capital efficient. I believe the development CapEx figure will serve as a superior indicator of that compared to the clinic figure we've disclosed historically, and that stems partly from this timeline issue. It also stems from the reality that we're constructing more home-only clinics, which are generally less expensive and aren't included in the clinic count we've historically disclosed. I believe the takeaway is the de novo keeps declining as NAG declines, as we shift more toward home. There might be a sort of extra delay tied to COVID, partly due to a temporary drop in NAG, partly because constructing clinics is simply difficult amid COVID. Concerning the commitment we made regarding capital efficiency, I believe we're still delivering on what we stated we would.
Matt Larew
analystUnderstood; that helps. I'd like to ask briefly regarding what you said about treatments that were missed. You noted, as I recall, that commercial patients typically are greater when it comes to transplants, yet what discrepancies did you observe across various payer classes regarding patterns of visits? Throughout this stretch, did those in the Medicare group generally experience more skipped treatments, and weren't missed treatments significantly reduced among commercial? I suppose, how did that appear across payer classes?
Javier Rodriguez
executiveRight, we did not separate that data according to payer class. Something that makes us quite pleased is that during this stretch, skipped treatments declined — which means our patients took the virus extremely seriously, looked after themselves, and we could look after them beyond the hospital setting. I'd say, given how the math comes out, this held true across every payer class. I can't state that for certain, since I never split it out by payer class. Broadly, we felt great about seeing a meaningful drop in hospitalizations among our chronic population.
Matt Larew
analystDid you notice any shift in where referrals came from during the quarter, or anything tied to COVID? Typically, I understand roughly 50% of your patients begin dialysis while in a hospital, so I'm just wondering, now that COVID has moved along and hospital visitation habits have shifted somewhat, what are you observing regarding origination?
Javier Rodriguez
executiveI believe what you're asking is whether the route by which patients reach us has altered — in other words, fewer people crashing into the hospital and instead coming to our center first. The brief response is that no meaningful difference has appeared in how patients arrive.
Matt Larew
analystOkay. Fair enough. Thanks.
Javier Rodriguez
executiveThank you.
Kevin Fischbeck
analystHey, I just want to ask about a few follow-ups. First off, clearly you landed at the bottom of your treatment guidance for this quarter, and it sounds like you might stay under that for a minimum of several more quarters. How sure are you that this is only because of COVID and not just the decline continuing that we've witnessed over the past couple of years, when you had a far greater growth rate a few years back? You've lowered that a few times. How much visibility do you actually have that this is something temporary and that we'll return to the one and a half to two and a half?
Javier Rodriguez
executiveKevin, let me walk you through some of the variables. Then, if you'd like to challenge the assumptions, feel free. Several variables interact with one another. Basically, what occurred during the quarter is that mortality went up. Like we've said, it leaned toward the older population. The acute volume, the acute treatments declined. In our view, that's clearly due to non-essential care getting postponed. We believe that is definitely tied to COVID. The incidence of our new patients declined. When we speak with our nephrologists, we generally think, at a high level, okay, your kidneys fail, you've got to go on dialysis. The truth is there's more nuance to it — you still have some renal function left. At times your nephrologist faces a choice. Are you better off beginning dialysis while you still have some renal function so you respond better to the therapy? At this moment, amid the pandemic, they're asking, "Would it be better to start you a bit later?" We observed our new patient incidence drop. We, naturally, observed no visitors as a result of travel restrictions; we observed a decline in transplants since transplants were clearly halted for a while, which essentially was an offset. As we've already discussed, we observed missed treatments fall, so that was likewise a boost to volume. Once we net all of that and provide you what we anticipate in the back end, our assumption is that in time, this will probably normalize aside from the effect on mortality over time.
Kevin Fischbeck
analystThat all tracks. So does that mean, sort of in answer to the previous question regarding how patients are showing up, that you aren't currently observing more patients crashing, yet you believe if this keeps up, we'll see that happen? Not that it's any kind of good news whatsoever, but it would at least suggest that underlying demand is stronger than what you're actually seeing.
Javier Rodriguez
executiveYes, that would be entirely speculative. I'm simply relaying what our nephrologists say about their practices, and most practices for a period, clearly, had been closed for care deemed non-essential. They continued making hospital rounds. What we expect at this point, now that we've spoken with our nephrologists and their practices have reopened, is that no dramatic shift has been observed by them. Naturally, that isn't scientific. We're merely passing along what we hear from our nephrology practices.
Kevin Fischbeck
analystUnderstood. I believe you mentioned before that this quarter exceeded expectations due to stronger productivity than anticipated. Is there any reason to believe those productivity improvements can't be sustained once things return to a more typical operating state, assuming COVID begins to fade next year? Are you able to keep that productivity up? I don't recall you listing it among the headwinds for 2021.
Javier Rodriguez
executiveYes. Productivity is going to be an intriguing topic. Naturally, certain elements will disappear. Patients will eventually resume visiting their doctors, and our benefit costs will rise again. When it comes to training costs and retention, my view is that those will be tightly tied to the economy, its performance, and how individuals feel about the value of their jobs and the sense of purpose we provide. Broadly speaking, one could argue it might persist, while someone else could contend it will revert to prior levels. My sense is that it will depend heavily on what happens with the wider economy and how COVID is affecting things at that time.
Kevin Fischbeck
analystAll right, great. Thanks.
Javier Rodriguez
executiveThank you.
Justin Lake
analystThank you. I have a few additional questions. First, Joel, your corporate and ancillary segments appear to have declined quite significantly from Q1 to Q2. I'm just wondering whether you could point to anything behind that and how we should view those figures for the second half.
Joel Ackerman
executiveYeah. Let me think about whether anything stands out. A severance charge was included. It came to roughly $12 million, and I'm trying to recall whether it fell in Q1 or Q2. I'll get back to you with that.
Jim Gustafson
executiveThe second quarter is the one I just mentioned, and it fell under Corporate. During the first quarter, we saw a sizable gain tied to foreign currency within Strategic Initiatives, which is where international sits.
Joel Ackerman
executiveCorrect.
Jim Gustafson
executiveIt moved somewhat in the opposite direction.
Joel Ackerman
executiveYes, thanks, Jim, I really do appreciate that. During the first quarter, foreign exchange gave us a $10 million benefit through international, and then in the second quarter that reversed into a $4 million hit.
Justin Lake
analystThat clears things up. Thank you. To return to what Whit asked, clearly regarding your remarks about COBRA and exchange enrollment coming in higher. Considering the direction the economy is heading, that's a fairly significant variable. Obviously, it sounds like things are surpassing expectations. It would help us to sort of grasp what the historical picture has been and what the current situation is. Could you provide even approximate figures?
Javier Rodriguez
executiveYeah. Although I won't provide approximate figures, and let me verify I'm addressing the correct question, Justin. Are you inquiring about the mix of COBRA versus other commercial insurance?
Justin Lake
analystNo — that's what I'm trying to get at. You mentioned that when people lose their jobs, there's been a fairly substantial rise in the count of those enrolling in COBRA exchanges, compared with what's typically observed during similar stretches.
Javier Rodriguez
executiveRight. At this point, without going into specifics, I'd simply restate my earlier point: our patients feel strongly about retaining their commercial insurance, and there are multiple reasons for that — family coverage being one, and some feel it improves their chances of receiving a transplant; in certain cases, it's clearly the least expensive option with the greatest amount of flexibility. They weigh these choices carefully, since they recognize it affects their lives in a significant way, given how much healthcare they use.
Justin Lake
analystOkay. Joel, you listed the 2021 headwinds and tailwinds, but Medicare Advantage's faster growth wasn't among the tailwinds you named for 2021. I'd like to know whether your position is that we shouldn't count on that having much effect next year — in other words, you don't believe it will ramp up relative to the last 2 or 3 years? If that's right, what's the reason?
Joel Ackerman
executiveWell, our messaging on Medicare Advantage has stayed fairly consistent, I'd say: 2021 isn't something we view as a giant inflection point for enrollment. Our expectation is that MA enrollment keeps increasing. Maybe it picks up somewhat more speed next year, but our perspective has simply differed from that of other players in the industry. Our sense is that many of our patients feel satisfied with their Medicare fee for service coverage. A certain amount of inertia exists. A single-year massive uptake just isn't something we foresee.
Justin Lake
analystUnderstood. It just seems to me that there's a fairly wide gap between huge adoption and what appears to be roughly a 2% annual rise in penetration, perhaps slightly above that. Correct. So are you actually saying you believe it will likely be the usual 200 to 300 basis point gain, like what we've observed over the past several years, rather than what I suspect some people anticipated, something closer to 500+?
Javier Rodriguez
executiveSure, allow me to step in, since you're working with the same data we have on this, Justin. What I can share is that within our population, approximately 25% of Medicare patients are in MA. The figure the industry cites is about 35%.
Justin Lake
analystRight.
Javier Rodriguez
executiveFolks keep asking, "So will the figure exceed 35? Will we hit 35 during the first year of enrollment?" Our consistent message, each quarter, has been that we expect a slower pace, and we believe that slower pace comes from several dynamics mentioned earlier today: part of the patient base lacks information, another part prefers things as they are, so never discount inertia. If someone tells you, "Sure, maybe there's something better for me, but I'm happy with what I have or it works fine for me," plenty of people simply aren't interested in making a switch, since the unfamiliar makes them uneasy. Our point is that for some, change is difficult, and in our view it will happen more gradually — and we might be mistaken. What we're trying to ensure is this: at one point, plenty of voices claimed the shift would arrive extremely quickly and the ramp would be sharp. They may turn out to be correct, yet we don't believe that's how it will unfold.
Justin Lake
analystAlright, I appreciate you taking the time to speak with us.
Javier Rodriguez
executiveMuch appreciated, Justin.
Pito Chickering
analystHi, everyone. Appreciate the chance to ask a couple more things. Because of how much time we have, I'll be quick. Could you take us back over how you priced on the commercial side in Q2, and would you say that's held fairly steady through 2020 up to now?
Javier Rodriguez
executiveMy apologies — could you repeat what you're asking about commercial pricing?
Pito Chickering
analystCould you share what happened with commercial pricing? Was there an increase during Q2, and has commercial pricing remained reasonably steady through 2020 as far as you can tell?
Javier Rodriguez
executiveRight. On commercial pricing, we have nothing worth flagging.
Pito Chickering
analystIn the second quarter, what portion of the productivity gains you recorded resulted from moving staff into the home setting?
Javier Rodriguez
executiveThat’s something I can’t answer. Joel, can you answer that? I mean, broadly speaking-
Joel Ackerman
executiveMy take is that breaking down the ins and outs of how productivity shifts from one quarter to the next isn't something we plan to do. What we're aiming to get across, I believe, is that our cost management work keeps paying off, and that's what's producing solid margins in the core. Going into that kind of granularity isn't something I see us doing.
Pito Chickering
analystAlright, and the last thing here is a point Javier brought up before on this call — if I recall correctly, it was that during Q2, 28 centers were opened. Like you said, that serves as a lagging indicator of the direction things are taking. Whenever we examine 2021 and think about how it separates between home clinics and standard clinics, what split would make sense, given those ultimately feed into where you’re looking to open clinics?
Javier Rodriguez
executiveThat number isn’t right in front of me, though Joel, hold me to it — for next year’s growth, between in-center and home centers, our figure comes to roughly 50/50, and that lands at about $3.52.
Joel Ackerman
executiveYou've got that right.
Pito Chickering
analystGreat. Thanks so much, everyone. I appreciate you taking the time.
Javier Rodriguez
executiveThanks, Ed.
Whit Mayo
analystThank you. You folks simply need to end our time here. I have an additional one, since a number of emails reached me regarding revenue per treatment. In the quarter, you posted $352. Subtract $7 for calcimimetics, and that brings us to $345. My estimate for the sequester came to roughly $1.60. That takes me to $344, and when you performed that same calculation in the prior quarter, the figure was $338. So between Q2 and Q1, you have $6 of growth. The real question, I suppose: given that your commercial mix stayed basically level relative to Q1, what produced that extra gain? Historically speaking, when we look back at earlier years, pricing doesn't show much seasonality. I'm just attempting to determine whether something else could be pushing that figure higher.
Joel Ackerman
executiveYes. Seasonality accounts for most of it. Because of certain bad debt dynamics, it seems we're experiencing somewhat greater seasonality this year, yet roughly two-thirds of that $6 — and your calculation is quite accurate — comes from seasonality. The remainder, I would describe as ordinary variations.
Whit Mayo
analystWhen you refer to bad debt, are you saying that these patients have already gone through their deductible completely?
Joel Ackerman
executiveYes. Once patients have worked their way through deductibles along with co-insurance, and a few additional dynamics come into play where bad debt is concerned, that is precisely what's happening. It matches what you would anticipate, in my view.
Whit Mayo
analystAlright. Nothing beyond that in terms of payer settlements or any odd items?
Joel Ackerman
executiveThere's nothing more. No, I don't have anything additional to flag.
Whit Mayo
analystOkay.
Joel Ackerman
executiveJustin brought this up with me before, asking if that RPT number is a reasonable one to use when modeling out the rest of the year, and I'd say yes, it is — think $3.38, $3.44, $3.45.
Whit Mayo
analystI appreciate you clearing that up.
Javier Rodriguez
executiveAlright, I want to express my gratitude for every one of the questions, and thanks for taking an interest in our company, and allow me to wrap up with 3 points. First, I simply want to restate how much pride I feel in the team's care and what they have achieved. They keep going without stopping, and that is a wonderful thing. Second, our core business remains solid. Third, we are still achieving significant progress regarding our abilities to push the care continuum forward spanning home, hospital, and in-center settings. We can't wait to talk with you once more in the next quarter. Take care and remain safe.
Operator
operatorThat concludes today's conference. Thank you all for your participation. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.